Non-invasive fibrosis testing moves closer to routine use
A new research briefing in Nature Medicine points to a meaningful shift in how advanced liver disease could be evaluated in people with metabolic dysfunction-associated steatotic liver disease, or MASLD. In the LITMUS imaging study, researchers assessed non-invasive alternatives to liver biopsy histopathology and found that elastography and elastography-based composite scores had sufficient diagnostic accuracy to evaluate advanced fibrosis and cirrhosis. The result matters because liver biopsy has long been treated as a reference method for staging disease, even though it is invasive, resource-intensive, and not easy to scale across large patient populations.
The study did not claim that all major diagnostic questions in MASLD are now solved without biopsy. The briefing makes a narrower and more important point: some fibrosis-related assessments may be ready for a different workflow, while the diagnosis of metabolic dysfunction-associated steatohepatitis, or MASH, still lacks non-invasive markers accurate enough to replace histopathology. That distinction is critical for clinicians, health systems, and developers of imaging and biomarker tools, because it suggests progress is uneven across the disease spectrum.
Why fibrosis staging matters in MASLD
MASLD is the current terminology for a common liver disease associated with metabolic dysfunction. Within that spectrum, clinicians are especially concerned about fibrosis, the buildup of scar tissue that can progress to cirrhosis and raise the risk of serious complications. Determining whether a patient has advanced fibrosis or cirrhosis is central to prognosis, surveillance, and treatment planning.
That is why the LITMUS finding stands out. If elastography-based methods can reliably evaluate advanced fibrosis and cirrhosis, they could reduce dependence on biopsy in one of the most clinically consequential parts of disease management. A shift like that would not just spare some patients an invasive procedure. It could also make repeat assessments more practical, support broader screening in specialist pathways, and help standardize evaluation across centers that already use imaging-based workflows.
The research briefing describes elastography and elastography-based composite scores as having sufficient diagnostic accuracy for those fibrosis endpoints. Based on the supplied source text, the study does not present this as a blanket replacement for every use of liver biopsy. Instead, it suggests that for evaluating advanced fibrosis and cirrhosis in MASLD, non-invasive testing has reached a threshold of performance that could change practice.
What the study did not solve
The same briefing also highlights the current limit of non-invasive testing. No markers in the study were accurate enough for diagnosing MASH. That negative finding is as important as the positive one. It shows that the field is not dealing with a single diagnostic problem, but with several related ones that require different levels of certainty and may need different tools.
MASH involves inflammatory liver injury within the broader MASLD spectrum, and the inability of current markers to diagnose it accurately enough means biopsy still retains an important role. In practical terms, health systems may be moving toward a split model: non-invasive methods for some fibrosis decisions, but histopathology still needed when the question is whether steatohepatitis is present.
For researchers and product developers, this is a reminder that success in fibrosis staging does not automatically translate into success in identifying inflammatory disease activity. Composite scores and imaging tools may continue to improve, but the briefing indicates that the current evidence has not closed that gap.
The significance of the LITMUS framework
The LITMUS program is designed around assessment and validation of imaging modality performance across the disease spectrum, and the references attached to the briefing point to a prospectively recruited cohort study with quality-control procedures for imaging biomarkers, liver histology evaluation, and blood-based markers. That context matters because diagnostic accuracy studies are only as useful as their consistency and comparability across sites and readers.
While the supplied text is brief, it places the new findings within a broader European effort to build stronger evidence around biomarker performance in fatty liver disease. That kind of structured validation is important if non-invasive tools are going to move from promising adjuncts to accepted replacements for specific clinical decisions.
The larger implication is methodological as much as clinical. Modern liver disease care increasingly depends on layered evidence from imaging, blood tests, and pathology rather than a single all-purpose gold standard. Studies like LITMUS help define where each tool belongs and where confidence is strong enough to retire an older approach in limited but meaningful settings.
What could change next
If the findings are integrated into practice guidelines and specialist workflows, the first changes are likely to appear in how patients with suspected advanced fibrosis are triaged and monitored. Elastography-based testing could be used more confidently to identify people who need closer surveillance for cirrhosis-related complications, while also reducing the number of cases sent directly to biopsy for fibrosis confirmation alone.
That would not eliminate the need for pathology expertise. Instead, it would reserve biopsy for harder questions, especially where MASH diagnosis or unresolved uncertainty still requires tissue evaluation. In other words, the likely near-term outcome is not the end of liver biopsy, but a narrower and more targeted role for it.
The research briefing therefore marks a practical step forward rather than a definitive endpoint. Non-invasive testing appears to be reaching clinical maturity for advanced fibrosis and cirrhosis in MASLD, but not yet for steatohepatitis. For patients and clinicians, that is still a consequential development. It suggests that one of hepatology’s most burdensome diagnostic tools may become less central in a major part of care, even as the field continues to search for better answers in the areas where biopsy still holds its ground.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com